Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)-Reference-Cited by-同舟云学术

Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Published:2017-03-20 Issue:5 Volume:176 Page:1297-1307
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Iskandar I.Y.K.¹,Ashcroft D.M.¹,Warren R.B.²,Evans I.²,McElhone K.²,Owen C.M.³,Burden A.D.⁴,Smith C.H.⁵,Reynolds N.J.⁶⁷,Griffiths C.E.M.²

Affiliation:

1. Centre for Pharmacoepidemiology and Drug Safety; Manchester Pharmacy School; The University of Manchester; Manchester Academic Health Science Centre; Room 1·134, 1st Floor, Stopford Building, Oxford Road Manchester M13 9PT U.K

2. Dermatology Centre; Salford Royal NHS Foundation Trust; The University of Manchester; Manchester Academic Health Science Centre; Manchester U.K

3. Department of Dermatology; East Lancashire Hospitals NHS Trust; Royal Blackburn Hospital; Blackburn U.K

4. Department of Dermatology; Western Infirmary; Glasgow U.K

5. St John's Institute of Dermatology; Guy's and St Thomas’ NHS Foundation Trust; London U.K

6. Dermatological Sciences; Institute of Cellular Medicine; Medical School; Newcastle University; Newcastle upon Tyne U.K

7. Department of Dermatology; Royal Victoria Infirmary; Newcastle Hospitals NHS Foundation Trust; Newcastle upon Tyne U.K

Funder

British Association of Dermatologists

Pfizer

Janssen Cilag

AbbVie

Novartis and Samsung Bioepis for providing pharmacovigilance services

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.15027/fullpdf

Reference36 articles.

1. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy;Brezinski;PlOS ONE,2012

2. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy;Papp;Br J Dermatol,2011

3. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study;Gordon;J Am Acad Dermatol,2006a

4. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis;Moore;J Am Acad Dermatol,2007

5. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy;Gordon;J Dermatol Treat,2006b

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan;Journal of Dermatological Treatment;2024-02-05

2. Causes of Autoimmune Psoriasis and Associated Cardiovascular Disease: Roles of Human Endogenous Retroviruses and Antihypertensive Drugs—A Systematic Review and Meta-analysis;2023-11-24

3. Improving the Accuracy of Biologic Drug Survival Data: The Increasing Prevalence of Off-Label Dosing Must Be Considered when Reporting Drug Effectiveness and Safety;Journal of Investigative Dermatology;2023-11

4. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry;British Journal of Dermatology;2023-10-17

5. Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States;Journal of Dermatological Treatment;2023-04-24